Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...
MedPage Today on MSN
Frontline targeted therapies plus R-CHOP boosts PFS in high-risk B-cell lymphomas
Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...
OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...
The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND ...
Add Yahoo as a preferred source to see more of our stories on Google. Few agents define SoC for first-line DLBCL Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has ...
Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...
Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results